Abstract Purpose: To investigate the effect of a low-dose oral contraceptive containing drospirenone/ethinylestradiol 3 mg/20 μg on endometrioma mean diameter. Methods: Fifty women with sonographic diagnosis of ovarian endometrioma and at least 12 months of therapy with drospirenone/ethinylestradiol 3 mg/20 μg, without previous adnexal surgery, were selected for this retrospective study. Endometrioma mean diameter measured with transvaginal ultrasonography and endometriosis-associated symptoms evaluated by a visual analogue scale (VAS) score (0-10) were reported at therapy prescription (baseline) and after 6, 12 and 18 months of treatment. Main outcome measures were endometrioma mean diameters and endometriosis-associated symptoms variations during the follow-up; differences between cyclic and continuous regimen were also considered. Results: A significant reduction in endometrioma mean diameter was observed during the follow-up. The reductions of mean diameter versus baseline values were significantly higher in continuous users than in cyclic users at 6 and 18 months of follow-up. No new endometriomas occurred. The dysmenorrhea VAS score significantly decreased during the follow-up. Conclusions: Drospirenone/ethinylestradiol 3 mg/20 μg seems to be effective in reducing endometrioma mean diameter. The continuous regimen seems to be associated with a greater reduction than the cyclic one.

Del Forno, S., Solfrini, S., Ferrini, G., Zannoni, L., Bertoldo, V., Monti, G., et al. (2013). Do low-dose oral contraceptives have an effect on ovarian endometrioma diameter and endometriosis symptoms?. JOURNAL OF ENDOMETRIOSIS, 5(4), 151-158 [10.5301/je.5000167].

Do low-dose oral contraceptives have an effect on ovarian endometrioma diameter and endometriosis symptoms?

Del Forno, Simona;SOLFRINI, SERENA;FERRINI, GIULIA;ZANNONI, LETIZIA;MONTI, GIORGIA;LEONARDI, DEBORAH;SERACCHIOLI, RENATO
2013

Abstract

Abstract Purpose: To investigate the effect of a low-dose oral contraceptive containing drospirenone/ethinylestradiol 3 mg/20 μg on endometrioma mean diameter. Methods: Fifty women with sonographic diagnosis of ovarian endometrioma and at least 12 months of therapy with drospirenone/ethinylestradiol 3 mg/20 μg, without previous adnexal surgery, were selected for this retrospective study. Endometrioma mean diameter measured with transvaginal ultrasonography and endometriosis-associated symptoms evaluated by a visual analogue scale (VAS) score (0-10) were reported at therapy prescription (baseline) and after 6, 12 and 18 months of treatment. Main outcome measures were endometrioma mean diameters and endometriosis-associated symptoms variations during the follow-up; differences between cyclic and continuous regimen were also considered. Results: A significant reduction in endometrioma mean diameter was observed during the follow-up. The reductions of mean diameter versus baseline values were significantly higher in continuous users than in cyclic users at 6 and 18 months of follow-up. No new endometriomas occurred. The dysmenorrhea VAS score significantly decreased during the follow-up. Conclusions: Drospirenone/ethinylestradiol 3 mg/20 μg seems to be effective in reducing endometrioma mean diameter. The continuous regimen seems to be associated with a greater reduction than the cyclic one.
2013
Del Forno, S., Solfrini, S., Ferrini, G., Zannoni, L., Bertoldo, V., Monti, G., et al. (2013). Do low-dose oral contraceptives have an effect on ovarian endometrioma diameter and endometriosis symptoms?. JOURNAL OF ENDOMETRIOSIS, 5(4), 151-158 [10.5301/je.5000167].
Del Forno, Simona ; Solfrini, Serena; Ferrini, Giulia; Zannoni, Letizia; Bertoldo, Valentina; Monti, Giorgia; Leonardi, Deborah; Labate, Antonio Maria...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/530794
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? ND
social impact